Merck Posts Quarterly Profit on Sales Growth
The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.
Merck’s struggles with HPV vaccine send stock to worst selloff in almost 17 years
Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...